abciximab

出典: meddic

アブシキシマブ

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/05/21 08:14:17」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients.
  • Siller-Matula JM1, Specht S1, Kubica J2, Alexopoulos D3, De Caterina R4, Hobl EL5, Jilma B5, Christ G6, Lang IM1.
  • British journal of clinical pharmacology.Br J Clin Pharmacol.2016 Jul 1. doi: 10.1111/bcp.13053. [Epub ahead of print]
  • OBJECTIVE: This study investigated whether the GPIIb/IIIa receptor blocker abciximab might be a successful bridging strategy to rapidly achieve sufficient levels of platelet inhibition in cases where prasugrel is used in morphine pre-treated ST-elevation myocardial infarction (STEMI) patients.METHOD
  • PMID 27366874
  • A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
  • Holmes LE1,2, Gupta R1,2, Rajendran S1,2, Luu J1,2, French JK1,2, Juergens CP1,2.
  • Cardiovascular therapeutics.Cardiovasc Ther.2016 Jun 21. doi: 10.1111/1755-5922.12203. [Epub ahead of print]
  • AIMS: To compare three glycoprotein IIb/IIIa receptor antagonists (GPIs) in terms of platelet inhibition and major adverse cardiac events (MACEs), and assess the rate of bleeding and MACEs between GPIs and co-administered P2Y12 agents.METHODS: Eighty-three ACS patients undergoing PCI with planned GP
  • PMID 27327862
  • Delayed severe abciximab-induced thrombocytopenia: A case report.
  • Piątek Ł1, Janion-Sadowska A2, Kurzawski J2, Grabowska U3, Janion M4.
  • Heart & lung : the journal of critical care.Heart Lung.2016 Jun 20. pii: S0147-9563(16)30100-5. doi: 10.1016/j.hrtlng.2016.06.003. [Epub ahead of print]
  • BACKGROUND: Thrombocytopenia is a possible side effect of routinely administered medical agents widely used in the management of patients with acute coronary syndromes (ACS). It is usually observed within 24 h after abciximab infusion. Differential diagnosis is challenging and the management controv
  • PMID 27340007

和文文献

  • Effect of Abciximab Therapy in Patients Undergoing Coronary Angioplasty for Acute ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock
  • De Felice Francesco,Tomassini Francesco,Fiorilli Rosario [他]
  • Circulation journal : official journal of the Japanese Circulation Society 79(7), 1568-1574, 2015-07
  • NAID 40020502432
  • Effect of Abciximab Therapy in Patients Undergoing Coronary Angioplasty for Acute ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock
  • De Felice Francesco,Tomassini Francesco,Fiorilli Rosario,Gagnor Andrea,Parma Antonio,Cerrato Enrico,Musto Carmine,Nazzaro Marco Stefano,Varbella Ferdinando,Violini Roberto
  • Circulation Journal 79(7), 1568-1574, 2015
  • … Background:The effect of abciximab on survival in patients with ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS) undergoing primary percutaneous coronary intervention (PCI) is not clear.Methods and Results:We evaluated outcome in 410 consecutive patients with STEMI and CS who underwent PCI treated without (n=123) or with (n=287) abciximab. … The groups with and without abciximab had similar survival at 1-year follow-up. …
  • NAID 130005083928
  • Effect of Abciximab Therapy in Patients Undergoing Coronary Angioplasty for Acute ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock
  • De Felice Francesco,Tomassini Francesco,Fiorilli Rosario,Gagnor Andrea,Parma Antonio,Cerrato Enrico,Musto Carmine,Nazzaro Marco Stefano,Varbella Ferdinando,Violini Roberto
  • Circulation Journal advpub(0), 2015
  • … Background:The effect of abciximab on survival in patients with ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS) undergoing primary percutaneous coronary intervention (PCI) is not clear.Methods and Results:We evaluated outcome in 410 consecutive patients with STEMI and CS who underwent PCI treated without (n=123) or with (n=287) abciximab. … The groups with and without abciximab had similar survival at 1-year follow-up. …
  • NAID 130005066290

関連リンク

Abciximab (previously known as c7E3 Fab), a glycoprotein IIb/IIIa receptor antagonist manufactured by Centocor and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary ...
20 Jun 2008 ... Learn about the prescription medication ReoPro (Abciximab), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling.

関連画像


押しても画像が表示されない場合はサーバが混雑しています。2週間ほどあけて、再度押下してください。


★リンクテーブル★
リンク元mab」「アブシキシマブ

mab」

  [★]

モノクローナル抗体

mab


アブシキシマブ」

  [★]

abciximab
レオプロ ReoPro


  • 血小板凝集抑制薬
  • GpIIb/IIIa受容体をブロックする。

参考

uptodate

  • . [charged] アブシキシマブ:医薬品情報 - uptodate [1]
  • . [charged] アブシキシマブ:患者向け医薬品情報 - uptodate [2]
  • . [charged] 冠動脈疾患における血小板糖蛋白IIb/IIIa受容体阻害剤に関する臨床試験:静脈内投与剤 - uptodate [3]
  • . [charged] 糖蛋白IIb / IIIa阻害剤による血小板減少症 - uptodate [4]




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡